Browse the evidence

High-intensity circuit training (HICT) produces strength and lean body mass gains equivalent to traditional strength training (TS) in trained women when sets are taken close to muscular failure, while significantly reducing total session time.

If you are a trained woman looking to save time, try High-Intensity Circuit Training. Perform 3 sets of 8-15 reps for each exercise with short rest (35s) between sets and longer rest (5min) between circuits. Crucially, you must push close to failure (RPE 8-9) to get the same strength and muscle gains as traditional training, but in less time.

Tirzepatide produces significantly greater monthly and annual weight loss, higher patient satisfaction, and improved quality of life compared to Semaglutide and Liraglutide in a Kuwaiti population.

If you are considering GLP-1 therapy for weight loss in Kuwait, Tirzepatide appears to offer the highest weight loss and satisfaction rates compared to Semaglutide and Liraglutide. Be aware that side effects like belching (Tirzepatide) or anxiety (Liraglutide) may influence your choice, and check government facility availability to manage costs.

Combination therapy of sibutramine (10 mg/d) and topiramate (100 mg/d) produces clinically meaningful weight loss (mean 10.2 kg at 36 months) with a tolerable safety profile in real-world clinical settings.

For individuals with obesity who cannot access newer, expensive medications, the combination of sibutramine (10mg) and topiramate (100mg) offers a cost-effective, clinically significant weight loss solution (approx. 10kg over 3 years). It requires medical supervision to manage potential side effects like increased blood pressure or paresthesia, but offers a viable alternative for long-term management in resource-limited settings.

Survodutide, a glucagon receptor/GLP-1 receptor dual agonist, induces significant body weight reduction in people with obesity and type 2 diabetes (T2D) when administered weekly via subcutaneous injection alongside lifestyle modifications.

If you have obesity and Type 2 Diabetes, standard diet and exercise changes often lead to weight regain. This trial investigates a weekly injection (survodutide) that targets both glucose and fat metabolism pathways. It is designed to be taken alongside a modest calorie deficit (500 kcal/day) and 150 minutes of weekly exercise. The dose is slowly increased to minimize stomach side effects, which are common but manageable. This approach aims to provide more durable weight loss than lifestyle changes alone, addressing the specific challenge that T2D can blunt weight loss efforts.

Semaglutide 2.4 mg combined with the WeGoTogether digital support program yields substantial long-term weight loss, with mean percent weight loss reaching -20.4% at 24 months in a real-world setting.

If you have a BMI of 25 or higher, starting semaglutide 2.4 mg and using a digital support app like WeGoTogether can help you lose a significant amount of weight over two years. The app provides reminders, coaching, and tools to help you stay on track. Expect to lose around 20% of your body weight by the end of two years, based on this study's findings.

GCGR-based multi-agonists (mazdutide, pemvidutide, survodutide, retatrutide) produce significantly greater weight loss than existing GLP-1 or GLP-1/GIP therapies by synergistically combining appetite suppression with increased energy expenditure.

If you have obesity and struggle with weight loss despite lifestyle changes, GCGR-based multi-agonists (like mazdutide, retatrutide, etc.) are emerging as highly effective treatments. They work by targeting multiple hormonal pathways to suppress appetite and increase energy expenditure, often resulting in greater weight loss than current GLP-1 drugs. While they are injectable and can cause GI side effects, starting with lower doses and titrating up can help manage these effects. Consult a healthcare provider to see if you are a candidate, especially if you have comorbidities like T2DM or CV disease.

Combining a Very Low-Calorie Ketogenic Diet (VLCKD) with liraglutide produces significantly greater weight loss and metabolic improvements compared to VLCKD alone, primarily through synergistic appetite suppression.

If you are struggling to lose weight with a very low-calorie ketogenic diet alone, adding liraglutide can significantly boost your results. In this study, adding the drug led to nearly 6kg more weight loss over 4 months. Be aware that you are much more likely to experience nausea or constipation, but for most participants, this did not stop them from completing the program. Consult a doctor to see if this combination is safe and appropriate for you, especially given the cost and side effect profile.

Professional athletic status, characterized by structured multidisciplinary training and personalized nutrition, is associated with significantly lower fat mass percentage and higher fat-free mass percentage compared to non-professional athletes.

If you are an athlete, the difference between amateur and pro body composition is significant. Pros have lower fat and more muscle. This isn't just genetics; it's the result of structured, supervised training and personalized diet. If you are not a pro, you can still improve by structuring your training and paying closer attention to your nutrition, even if you can't access a full pro team.

Resistance training significantly improves muscle strength, lean mass, and walking ability in older adults with sarcopenia, with optimal cumulative training volumes of approximately 1,043 minutes for muscle strength and 2,716 minutes for walking ability.

For older adults with sarcopenia, resistance training is the most effective non-pharmacological intervention. Aim for a total training volume of about 1,043 minutes to maximize muscle strength and 2,716 minutes to maximize walking ability. This typically translates to moderate intensity (60-80% of your one-rep max) performed 2-3 times per week. Consistency in total training time is key to reversing muscle loss and improving mobility.

Post-bariatric physical activity adherence is significantly improved when interventions utilize low-impact modalities (aqua sports, walking, cycling) delivered in small groups (6-10 people) within a stigma-free environment, as opposed to standard gym settings.

If you have had bariatric surgery, do not force yourself into a standard commercial gym if it makes you anxious. Look for or request small group sessions (6-10 people) focusing on low-impact activities like swimming, walking, or cycling. This environment reduces the fear of judgment and is more likely to help you stick with exercise long-term.

Tirzepatide induces rapid, clinically significant weight loss and fat mass reduction within 30 days while preserving fat-free mass in adults with overweight or obesity.

If you are starting tirzepatide for obesity, expect to lose about 4 kg in the first month, mostly from fat stores rather than muscle. This happens even if you are still in the early dose-escalation phase. Adhering to the prescribed lifestyle changes (Mediterranean diet and walking) is part of the protocol, but the drug itself drives significant early fat loss. This rapid initial response can help maintain motivation for long-term treatment.

Treating 50% of moderate- to high-risk obesity patients (Class II and III, excluding diabetes) with 2.4 mg weekly semaglutide plus lifestyle intervention for 68 weeks reduces population prevalence of these obesity classes and yields significant annual societal cost savings.

For healthcare policymakers and insurers, implementing widespread access to 2.4 mg weekly semaglutide for moderate-to-high risk obesity (excluding diabetics) alongside lifestyle programs can significantly reduce the prevalence of severe obesity and save billions in societal costs over time. This requires ensuring affordability and addressing long-term adherence.

Biathletes should consume 6–12 g/kg/day of carbohydrates, adjusted by training intensity, to maintain high carbohydrate availability and support glycogen resynthesis between sessions.

Aim for 6 to 12 grams of carbohydrates per kilogram of body weight every day. Adjust this amount up on heavy training days and down on rest days. Prioritize carbohydrate-rich foods at every meal and use high-carb snacks between sessions to keep your energy stores full.

Biathletes should consume a recovery meal containing approximately 0.3 g/kg of protein and 1.2 g/kg of carbohydrates immediately after key training sessions or races to optimize glycogen resynthesis and muscle repair.

Within 30 minutes of finishing a hard session or race, eat a meal with 0.3 grams of protein and 1.2 grams of carbohydrates per kilogram of body weight. A recovery shake is a convenient option if you can't eat a full meal immediately.

Measuring Resting Metabolic Rate (RMR) and adjusting caloric goals based on weight loss-induced metabolic adaptations prevents weight loss plateaus and optimizes energy balance.

If you are not losing weight despite following a standard diet, your metabolism may have adapted. Get your Resting Metabolic Rate (RMR) tested using a portable device or metabolic cart. Use this number to calculate a personalized calorie goal that creates a deficit relative to YOUR specific energy needs, not a generic number. Re-test as you lose weight to adjust your plan.

Professional supervision is a critical factor for achieving continued body composition improvements in resistance-trained individuals.

To continue making progress after your initial gains, seek professional guidance. If full-time coaching is too expensive, consider lower-cost options like online coaching, periodic in-person sessions, or using self-regulation tools like RPE and RIR to ensure you are training with sufficient intensity and proper programming.

GLP-1 receptor agonists and co-agonists induce significant weight loss (10–25%) in adults without diabetes, with newer multi-agonists (e.g., tirzepatide, retatrutide) demonstrating superior efficacy compared to earlier single-agonists.

If you have obesity or overweight with related health issues, GLP-1 medications (like semaglutide or tirzepatide) are now a standard, effective treatment option that can produce significant weight loss (10-25%), comparable to surgery. Newer oral options exist, and these drugs work independently of diabetes status. Consult a doctor to see if you qualify, as they are typically reserved for those who haven't succeeded with lifestyle changes alone.

Retatrutide (LY3437943) administered subcutaneously once weekly produces significant, dose-dependent weight loss and improved glycaemic control in adults with obesity or type 2 diabetes, outperforming placebo and dulaglutide at higher doses (8-12 mg).

Retatrutide is a once-weekly injection that significantly reduces body weight (up to 26 kg in trials) and improves blood sugar control in people with obesity or type 2 diabetes. It works by targeting three hormone receptors (GIP, GLP-1, Glucagon). Higher doses (8-12 mg) are more effective but may cause mild gastrointestinal side effects that usually improve over time. It appears more effective than some existing treatments like dulaglutide for weight loss.

Adjuvant GLP-1 RA therapy combined with high-protein intake (≥1.2 g/kg/day) and resistance training is necessary to counteract metabolic adaptation and preserve lean body mass after bariatric surgery.

After bariatric surgery, your body fights back against weight loss by slowing your metabolism. If you experience weight regain, adding a GLP-1 medication can help. Crucially, to prevent losing muscle along with fat, you must eat at least 1.2 grams of protein per kilogram of body weight daily and engage in supervised resistance training. This combination helps maintain your metabolic health and muscle mass.

Tirzepatide treatment in patients with obesity and type 1 diabetes results in significant weight loss (median 8.5-12.2%) and reduced insulin requirements without increasing hypoglycemia or serious adverse events.

If you have Type 1 Diabetes and obesity, Tirzepatide is a viable option for weight loss and reducing insulin needs. Start with a low dose (2.5mg) and increase slowly to minimize nausea. You must work with your doctor to adjust your insulin doses to prevent hypoglycemia. Combine the medication with a modest calorie deficit and regular exercise for best results.

A combined supplementation protocol of creatine, beta-alanine, and caffeine yields superior strength gains (+15.2%) and faster recovery (22 hours) in powerlifters compared to protein supplements or no supplements.

If you are a powerlifter, consider a stack of creatine, beta-alanine, and caffeine. In this study, this combination increased strength by 15.2% and reduced recovery time to 22 hours over 8 weeks, outperforming protein-only supplements and no supplements.

Balanced macronutrient intake (1.6-2.2g protein/kg, 4-6g carbs/kg) results in significantly greater strength gains (12.5%) and faster recovery (24 hours) compared to protein or carbohydrate deficits.

Eat a balanced diet with 1.6-2.2g of protein per kg of body weight and 4-6g of carbohydrates per kg. This supports maximum strength gains and faster recovery (24 hours) compared to restricting either nutrient.

Adapted physical activity (APA) consisting of 3 moderate-intensity sessions per week (20-30 minutes) leads to a statistically significant gain in lean mass (average +0.64%) in hospitalized hematology patients.

For hematology patients, 3 short (20-30 min) moderate sessions per week of light resistance and balance exercises (like yoga or Pilates with light weights) can help preserve or slightly increase muscle mass and reduce fatigue, provided blood counts are monitored and sessions are paused if counts drop too low.

Whey protein is the only protein source shown to have statistically significant effects on both endurance performance and muscle strength in this meta-analysis.

If you use protein supplements for performance, whey protein is the only source with demonstrated significant benefits for both endurance and strength in this analysis. Other sources (soy, casein, etc.) did not show significant effects.